secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2024-06-10T23:59:59+00:00
Accession:  0001193125-24-157911
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology appoints Michael A. Metzger (CEO of Syndax) to board effective June 10, 2024
--------------------------------------------------------------------------------

- Michael A. Metzger appointed to Pyxis Oncology Board as Class II director, effective June 10, 2024.
- Metzger is CEO of Syndax Pharmaceuticals (Nasdaq: SNDX) and has over 25 years biopharma experience.
- He will serve on Audit and Compensation Committees; received stock options for 70,683 shares vesting over three years.
- Board determined Metzger qualifies as independent director under Nasdaq standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000119312524157911/0001193125-24-157911-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000119312524157911/d843596d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-157911

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer